Israel Hereditary Cancer Testing Market to 2032
Overview
The Israel Hereditary Cancer Testing Market is expected to reach a 37.36 USD Million by 2032 and is projected to grow at a CAGR of 16.00% from 2025 to 2032.
Israel Hereditary Cancer Testing Market 2018-2032 USD Million
Israel Hereditary Cancer Testing Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 17.21 USD Million
- Projected Market Size (2032): 37.36 USD Million
- CAGR (2025-2032): 16.00%
Key Findings of Israel Hereditary Cancer Testing Market
- The Israel Hereditary Cancer Testing Market was valued at 17.21 USD Million in 2024.
- The Israel Hereditary Cancer Testing Market is likely to grow at a CAGR of 16.00% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Direct Tender in Distribution Channel Segment accounted for the largest share of the market with a revenue of 12.23 USD Million
- The fastest growing segment Hospitals in End Users Segment grew Fastest with a CAGR of 16.55% during the forecast period from 2024 to 2032.
Israel Hereditary Cancer Testing Market Scope
- Retail Sales
- Direct Tender
- Others
- Laboratories
- Radiology Centres
- Diagnostics Centers
- Clinics
- Hospitals
- Multiple Endocrine Neoplasias (MEN) Syndrome
- Von Hippel-Lindau Disease
- Li-Fraumeni Syndrome
- Familial Adenomatous Polyposis (FAP)
- Hereditary Leukemia and Hematologic Malignancies Syndrome
- Lynch Syndrome
- Cowden Syndrome
- Hereditary Breast & Ovarian Cancer Syndrome
- Microarray
- Sequencing
- Polymerase Chain Reaction (PCR)
- Lab Tests
- Imagining
- Biopsy
- Single Site Genetic Test
- Multi Panel Test
Israel Hereditary Cancer Testing Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2020 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 17.21 USD Million |
| Market Value in 2032 | 37.36 USD Million |
| CAGR (2025-2032) | 16.00% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Distribution Channel,End Users,Disease,Technology,Diagnosis,Test |
Regional Insights:
-
Leading Market (2024-2032): Israel, leading in terms of revenue 17.21 USD Million in 2024
- Key Country: Israel, leading in terms of revenue with value of 17.21 USD Million in 2024.
Segments and Scope
-
Israel Hereditary Cancer Testing Market to 2032, By Distribution Channel
- Direct Tender is the largest segment in Israel Hereditary Cancer Testing Market to 2032 with a revenue of 12.23 USD Million in the year 2024.
- Direct Tender is the Fastest growing segment in Israel Hereditary Cancer Testing Market to 2032 with a Growth rate of 16.15 % in forecast period 2025-2032.
-
Israel Hereditary Cancer Testing Market to 2032, By End Users
- Hospitals is the largest segment in Israel Hereditary Cancer Testing Market to 2032 with a revenue of 7.25 USD Million in the year 2024.
- Hospitals is the Fastest growing segment in Israel Hereditary Cancer Testing Market to 2032 with a Growth rate of 16.55 % in forecast period 2025-2032.
-
Israel Hereditary Cancer Testing Market to 2032, By Disease
- Hereditary Breast & Ovarian Cancer Syndrome is the largest segment in Israel Hereditary Cancer Testing Market to 2032 with a revenue of 10.45 USD Million in the year 2024.
- Hereditary Breast & Ovarian Cancer Syndrome is the Fastest growing segment in Israel Hereditary Cancer Testing Market to 2032 with a Growth rate of 16.51 % in forecast period 2025-2032.
-
Israel Hereditary Cancer Testing Market to 2032, By Technology
- Polymerase Chain Reaction (PCR) is the largest segment in Israel Hereditary Cancer Testing Market to 2032 with a revenue of 11.43 USD Million in the year 2024.
- Polymerase Chain Reaction (PCR) is the Fastest growing segment in Israel Hereditary Cancer Testing Market to 2032 with a Growth rate of 16.43 % in forecast period 2025-2032.
-
Israel Hereditary Cancer Testing Market to 2032, By Diagnosis
- Biopsy is the largest segment in Israel Hereditary Cancer Testing Market to 2032 with a revenue of 8.06 USD Million in the year 2024.
- Biopsy is the Fastest growing segment in Israel Hereditary Cancer Testing Market to 2032 with a Growth rate of 16.30 % in forecast period 2025-2032.
-
Israel Hereditary Cancer Testing Market to 2032, By Test
- Multi Panel Test is the largest segment in Israel Hereditary Cancer Testing Market to 2032 with a revenue of 11.56 USD Million in the year 2024.
- Multi Panel Test is the Fastest growing segment in Israel Hereditary Cancer Testing Market to 2032 with a Growth rate of 16.36 % in forecast period 2025-2032.
Israel Hereditary Cancer Testing Market Company Share Analysis
| Company Name |
|
||
| PerkinElmer Inc. | |||
| illumina, inc. | |||
| Abbott | |||
| Eurofins Scientific | |||
| LifeLabs Genetics | |||
Israel Hereditary Cancer Testing Market Geographical Sales Distribution, 2018-2032 USD Million
Israel Hereditary Cancer Testing Market Company Profiling
Industry Related Reports
Frequently Asked Questions
Israel Hereditary Cancer Testing Market Scope
- Retail Sales
- Direct Tender
- Others
- Laboratories
- Radiology Centres
- Diagnostics Centers
- Clinics
- Hospitals
- Multiple Endocrine Neoplasias (MEN) Syndrome
- Von Hippel-Lindau Disease
- Li-Fraumeni Syndrome
- Familial Adenomatous Polyposis (FAP)
- Hereditary Leukemia and Hematologic Malignancies Syndrome
- Lynch Syndrome
- Cowden Syndrome
- Hereditary Breast & Ovarian Cancer Syndrome
- Microarray
- Sequencing
- Polymerase Chain Reaction (PCR)
- Lab Tests
- Imagining
- Biopsy
- Single Site Genetic Test
- Multi Panel Test
Frequently Asked Questions
Israel Hereditary Cancer Testing Market Company Profiling
Frequently Asked Questions
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.